The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma

SIMPLE SUMMARY: Immune checkpoint inhibitors (ICIs) have significantly changed the treatment paradigm in metastatic renal cell carcinoma (mRCC) and brought an unprecedented durable response. However, there is still a significant proportion of patients who do not response to ICIs, and there are no bi...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yu-Wei, Tucker, Matthew D., Brown, Landon C., Yasin, Hesham A., Ancell, Kristin K., Armstrong, Andrew J., Beckermann, Kathryn E., Davis, Nancy B., Harrison, Michael R., Kaiser, Elizabeth G., McAlister, Renee K., Schaffer, Kerry R., Wallace, Deborah E., George, Daniel J., Rathmell, W. Kimryn, Rini, Brian I., Zhang, Tian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367298/
https://www.ncbi.nlm.nih.gov/pubmed/35954493
http://dx.doi.org/10.3390/cancers14153830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367298/
https://www.ncbi.nlm.nih.gov/pubmed/35954493
http://dx.doi.org/10.3390/cancers14153830

Ejemplares similares